Late-breaking registry data at europcr congress demonstrate reduced paravalvular leak and low permanent pacemaker rates for the acurate neo2™ aortic valve system

Marlborough, mass., may 18, 2021 /prnewswire/ -- data presented at hotline and late-breaking trial sessions today at the europcr 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (pvl) and permanent pacemaker implementation (ppi), of the boston scientific (nyse: bsx) acurate neo2™ aortic valve system within the investigator-initiated early neo2 registry1 and ital-neo registry2 studies.
BSX Ratings Summary
BSX Quant Ranking